Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients
Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares are higher during Tuesday’s premarket session as the company is discussing positive results from its recent clinical study.
Positive Data From Inflammatory Bowel Disease Study
Teva and Sanofi SA (NASDAQ:SNY) released positive results on Tuesday from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human monoclonal antibody targeting TL1A.
The study demonstrated durable clinical efficacy maintained over 44 weeks in patients with ulcerative colitis and Crohn’s disease.
The study involved 130 patients who initially responded to duvakitug in the induction phase, and both doses of duvakitug were well tolerated.
Patients were re-randomized to receive either a 450 mg or 900 mg subcutaneous dose of duvakitug every four weeks for up to a total of 58 weeks of exposure.
Ulcerative colitis: 58% (900 mg) and 47% (450 mg) of patients treated with duvakitug achieved the primary endpoint of clinical remission.
Crohn’s disease: 55% (900 mg) and 41% (450 mg) of patients treated with duvakitug achieved the primary endpoint of endoscopic response.
In both patient groups, consistent benefits were observed across additional efficacy endpoints.
Technical Analysis
Currently, the stock is trading 6.3% below its 20-day simple moving average (SMA) and 10.5% below its 100-day SMA, indicating short-term weakness. Shares have increased 105.07% over the past 12 months and are currently positioned closer to their 52-week highs than lows.
The RSI is at 50.00, which is considered neutral territory, while MACD is below its signal line, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $37.50
- Key Support: $30.50
Analyst Consensus & Recent Actions
The stock carries a Buy Rating with an average price target of $31.75. Recent analyst moves include:
- Goldman Sachs: Buy (Raises Target to $45)
- Barclays: Overweight (Raises Target to $38)
- Scotiabank: Sector Outperform (Raises Target to $40)
Top ETF Exposure
- iShares MSCI Israel ETF (NYSE:EIS): 9.59% Weight
- ARK Israel Innovative Technology ETF (BATS:IZRL): 2.37% Weight
- VanEck Israel ETF (NYSE:ISRA): 10.48% Weight
TEVA Price Action: Teva Pharmaceutical shares are up 2.85% at $34.94 and SNY 0.26% at $46.13 during premarket trading on Tuesday, according to Benzinga Pro data.
Photo via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Zoom (ZM.US) gets a bullish rating from Citi ahead of earnings: AI monetization signals emerge, target price raised to $131
Citibank has issued a forecast ahead of Zoom's Q3 financial report: Two major signals from channel partner surveys and Analyst Day both reinforce its view of a "moderate acceleration in the second half of the year."

JPMorgan: The CUDA moat is crumbling, and Nvidia faces real challenges beyond the CEO's departure
JPMorgan points out that Nvidia’s share in the 2026 compute protocol will drop to just 28%, with strong competition emerging from AMD, Google TPU, and others. Meanwhile, CUDA’s moat was breached by AI in only three days. The open-source market is facing tightened regulation and increased risks of export compliance. Although Nvidia’s current valuation remains attractive, both major drivers supporting high growth expectations have been undermined.
Bridgewater's $23 Billion Portfolio Reshuffle: Drops Google (GOOGL.US) and Amazon (AMZN.US), Increases Holdings in AI Hardware and Energy
Bridgewater's Q3 portfolio was restructured, with a total market value of $23 billion. The fund significantly increased holdings in AI hardware and energy stocks such as Qualcomm and Micron, reduced positions in Google, Amazon, and S&P 500 ETF, and fully exited industrial stocks like Union Pacific, with a notable increase in the weighting of the healthcare sector.

